You have   6 free profiles   left this month    Start Your Free Trial ➤
Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there? View on RelSci Pro ➤

Sanuj Ravindran

Chief Executive Officer-in-Residence at Bridgebio Pharma LLC
Overview
Relationships
In The News
Paths
Education
Memberships
Career History
Boards & Committees
Transactions
Awards & Honors

Sanuj Ravindran

Chief Executive Officer-in-Residence at Bridgebio Pharma LLC

Overview

Age
46 (Born 1972)
Notable Companies
PellePharm, Inc.
Awards
1
Board Seats
8
Number of Relationships
This person is connected to 1,595 people.

Relationships See Details


Venture Partner at Radius Ventures LLC

Senior Analyst at Mehta Partners LLC

Co-Founder at Radius Ventures LLC

Co-Founder at PellePharm, Inc.

Co-Founder & Director at PellePharm, Inc.

Co-Founder at PellePharm, Inc.

Co-Founder at Bridgebio Pharma LLC

Professional at LR Management Company LLC

Director at Burrill & Co. LLC

Professor, Law School at Pace University - New York
See 1,585 more listings with RelSci Professional.

In The News See More

RelSci
January 5, 2018
RelSci
January 5, 2018
FierceBiotech
January 5, 2018
PR Newswire
January 4, 2018
Business Wire
January 4, 2018
See full news coverage and complete stories with RelSci Professional.

Paths to Sanuj Ravindran

Sanuj Ravindran
You
Connections via Relationship Science
Sanuj Ravindran
Sync your contacts to see how you can connect with Sanuj Ravindran.

Educational Background

MD 
MBA 
The Kellogg School of Management (The Kellogg School or Kellogg) is the business school of Northwestern University in Evanston, Illinois, with additional campuses in downtown Chicago, Illinois and Miami, Florida. Kellogg offers full-time, part-time, and executive programs, and partners with schools in China, France/Singapore, India, Hong Kong, Israel, Germany, Canada, and Thailand.Founded in 1908 in downtown Chicago as a part-time evening program, the school was chartered to educate business leaders with "good moral character.
BA with Honors 
Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. In 1853 the founders purchased a 379-acre tract of land on the shore of Lake Michigan 12 miles north of Chicago. They established a campus and developed the land near it, naming the surrounding town Evanston in honor of one of the University's founders, John Evans. After completing its first building, its first building in 1855, Northwestern began classes that fall with two faculty members and 10 students. Northwestern has three campuses and a total of 12 Schools and Colleges (one of which is located in South Florida. Two campuses are located on Lake Michigan, a 240-acre campus in Evanston, the first suburb north of Chicago, and a 25-acre campus in Chicago. One campus is located in Doha, Qatar. Northwestern University combines innovative teaching and pioneering research in a highly collaborative environment that transcends traditional academic boundaries. It provides students and faculty exceptional opportunities for intellectual, personal and professional growth in a setting enhanced by the richness of Chicago.

Memberships

Fellow
Current
The Society of Kauffman Fellows is a network of venture capitalists operating at 160 venture firms and corporate venture groups in 26 countries on 6 continents, collectively deploying $50B in venture capital.

Career History

Chief Executive Officer
2018 - Current
PellePharm is developing patidegib, a novel hedgehog pathway inhibitor, to mitigate the tumor burden in patients with basal cell carcinomas (BCCs), including those in Gorlin Syndrome, a devastating rare genetic skin disease. The company is focused on developing and commercializing this treatment to reduce the burden of disease and improve quality of life by potentially reducing invasive and painful surgeries and the scarring that often accompanies them. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor exclusively licensed from Infinity Pharmaceuticals. Patidegib is currently being studied in a phase 2 clinical trial for the treatment of sporadic BCCs.
Chief Executive Officer-in-Residence
2018 - Current
BridgeBio Pharma LLC discovers and develops pharmaceutical drugs for patients with genetic diseases. The firm offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.
Vice President-New Business Ventures
2012 - 2015
The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.
Chief Business Officer
2016 - 2017
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.
Professional
2007 - 2010
Radius Ventures invests in leading-edge, growth equity and expansion-stage in healthcare and life sciences companies across all major sectors including biotechnology, medical devices, healthcare services and healthcare information technology. The firm looks for companies with exceptional management teams with strong track records, disruptive technologies and services, attractive market adoption dynamics, substantial barriers to competitive entry, highly profitable and sustainable business models, significant valuation inflection points expected in the near to mid-term and, strong prospects for the firm to leverage their network and experience to impact corporate development. Radius Ventures typically invest up to $10 million over initial and subsequent financing rounds, as a lead or syndicate investor.
Managing Director
Prior
Asia Pacific Healthcare is invests in the companies operation in the fields of healthcare and life sciences sectors. The firm provides financing for growth capital requirement.
Advisor, Financings, Partnering & Mergers & Acquisitions, Healthcare Investment Banking Group
Prior
Merrill Lynch is one of the world’s premier providers of wealth management, securities trading and sales, corporate finance and investment banking services.
National Cancer Institute Research Fellow
Prior
Memorial Sloan-Kettering Cancer Center — the world's oldest and largest private cancer center — has devoted more than a century to patient care and innovative research, making significant contributions to better understand, diagnose, and treat cancer. As one of the nation's premier cancer centers, Memorial Sloan-Kettering is one of only 41 institutions in the United States that have been designated Comprehensive Cancer Centers by the National Cancer Institute.
Professional
Prior
MLAM's worldwide approach to equity investing uses a philosophy of identifying relative value among individual stocks and stock markets by focusing primarily on two variables: reinvestment rate and the price-to-book value ratio.There are seven additional screens employed to further refine the process. The factors used to identify value include price-to-cash flow, price-to-earnings ratios, past and future earnings growth and dividend payouts. For asset allocation, a country whose market valuation measurements seem consistently above or below world averages or its own historical averages are over or under-weighted accordingly. The degrees of over or under-weighting are determined by relative economic prospects as measured by the outlook for GNP, inflation and interest rates of each country and their impact on currency movements.By combining a value approach to individual stock selection with asset allocation by country, the firm seeks to achieve consistent performance relative to international equity indexes.MLAM combines top-down and bottom-up analysis and uses proprietary models as part of their research process. Their funds are team-managed.
Member-Editorial Board
Prior
The Society of Kauffman Fellows is a network of venture capitalists operating at 160 venture firms and corporate venture groups in 26 countries on 6 continents, collectively deploying $50B in venture capital.

Boards & Committees

Corporate Boards ▾
Member, Advisory Board
Current
Member, Board of Directors
Prior
Burrill & Co.'s venture capital activities focus exclusively on life science companies whose technologies and products are applicable across range of life science sub-sectors including: (1) human healthcare therapeutics and diagnostics/devices (2) health/wellness (3) agricultural biotechnology (4) biofuels and (5) industrial biotechnology, biomaterials and bioprocesses. In addition, to sector diversification, the firm also diversifies across investment stage. In general, most of their investments are in the start-up through mezzanine stage. Most of the firm's investments are made in series A and B rounds. They do invest in public entities. Burrill & Co. principally invests in the US and Europe. The firm's professionals usually serve on the board of directors of each portfolio company and, when necessary, assist with operational activities. Investments tend to average from $5 million to $15 million over the life of a company.Burrill & Co.'s private equity investments focus on investments in undervalued small-cap and mid-cap public companies and selected buy-outs and spin-outs from pharmaceutical, biotechnology and other life sciences entities. The firm seeks to acquire significant equity positions often through PIPEs and to optimize opportunities for future equity financing, acquisitions and divestitures.
Board Member
Prior
Resolvyx Pharmaceuticals, Inc. discovers and develops therapeutics for inflammatory diseases. Its products include RX-10001, RX-10045 and RX-20001. The firm's focus is to develop a new class of medicines called Resolvins for the treatment of a range of ophthalmic diseases. The company was founded by Daniel Goodman, Charles N. Serhan, Per Gjorstrup and Thomas E. Van Dyke in 2005 and is headquartered in Cambridge, MA.
Member, Board of Directors
Prior
Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA.
Board Observer
Prior
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
Observer
Prior
Predictive Health Technologies, Inc. provides healthcare technology services. The company was founded by Ralph D. Snyderman and Jason M. Langheier in 2004 and is headquartered in Durham, NC.
Observer
Prior
diaDexus is a privately held biotechnology company that is focused on the discovery, development and commercialization of novel, patent protected diagnostic products with high clinical value. diaDexus makes a difference by developing innovative products with clinical value to address significant unmet medical needs in the cardiovascular field.
Non-Profit Boards ▾
Member, Editorial Board
Current

Transactions

Details Hidden
aTyr Pharma, Inc. raised money in a private placement transaction

Awards & Honors

Professional Certification
Board Certification - American Board of Internal Medicine

Other Affiliations

You've reached your 7 free profiles limit this month.

Upgrade to RelSci Pro today to enjoy unlimited profile views and much more!

Start My Free Trial
Still not convinced? Check out our full listing of features here.